Novo Nordisk and UnitedHealth: Two Plunges, Two Opposing Theses

Novo Nordisk and UnitedHealth: Buying the Falling Knife

How much does a stock have to fall before it stops being an opportunity and starts being a trap? That is the question underpinning a stock market watch on two giants in freefall: Danish pharmaceutical company Novo Nordisk and US insurer UnitedHealth. One lost what made it great; the other lives under the shadow of several legal proceedings. And in the meantime, people are buying as everything falls.

Why Novo Nordisk and UnitedHealth Are Not the Same

The most common diagnosis starkly separates the two cases. Novo Nordisk lost the monopoly that propelled it in its day: without a successful new patent, returning to highs is a pipe dream. UnitedHealth, on the other hand, is weighed down by the impact of the attack on its CEO and questioned management, but it remains, as is argued, the largest health insurer in the United States and retains solid numbers.

The difference in scale is seen in the accounting details: Novo's book value per share is around 4 euros, compared to the insurer's 103 dollars. With that starting point, some are clear and don't even consider choosing the Danish company.

Where Is Novo Nordisk's Floor?

Here the real problem begins. According to the narrative in the thread, one day it dropped 23% and the next day it kept falling. The year-to-year low was 36 euros, and there were purchases at 43; then came the drop to 37 and then to the 31 euros mentioned. The floor, the most prudent say, "has to be below 30." Translation: nobody has found the safety net.

The punishment is not exclusive to the Danish company. In a single session, Eli Lilly dropped 14.15%, its main direct competitor in the GLP-1 treatment business. When the entire sector is hit, distinguishing the signal from the noise becomes a risky sport.

The Danish Dividend That Gets Lost Along the Way

A tax detail that often goes unnoticed, as explained by a participant, changes the return calculation. Denmark would apply a withholding tax of 27%; Spain, 19%. There would be no agreement between the two countries, so there would be no way to deduct the usual 15% or claim the excess. A 4% dividend would net, in the end, 2%.

The solution circulating among more veteran investors: buy the German stock, traded in euros, and thus avoid the currency exchange. The withholding tax would remain at only the Spanish 19%. Less volume, but the dividend arrives in full.

UnitedHealth and the Alleged Pending Fraud

The insurer's story is different. Its fundamental analysis reads positively, but it faces several legal proceedings for alleged fraud against the federal government and, as is pointed out, would still be trading above its comparables. The legal risk is not closed, and that weighs more than any chart.

Playing against that antiestéticar is another piece of data: both US congressmen from the two major parties and executives linked to the company have been buying heavily, as is argued. A 3% dividend yield at these prices, for those who hold on, is also not negligible.

The Day Novo Was Worth More Than the Entire Ibex

Hemerology helps to size the collapse. In 2024, Novo Nordisk's capitalization came to exceed the combined value of the 35 largest Spanish listed companies, according to data circulating in the thread. That was read as unstoppable. Today, the same company is, for some participants, the recurring example of how a downward trend crushes any rebound and becomes the perfect bait to catch new capital.

The market's focus, meanwhile, has shifted to artificial intelligence and semiconductors. The health giants were left out of the spotlight.

Some average down with patience, and some wait. Others have already pulled out. At these prices, anyone would say the bottom is just around the corner.